Out of the participants with diagnosed diabetes (n=33), 75.8% (n=25) were prescribed metformin, 15.2% (n=5) sulfonylurea, 3.03% (n=1) Dipeptidyl Peptidase 4 inhibitors (DPP-4), while 12.1% (n=4) reported to be taking Sodium-glucose Cotransporter-2 inhibitors (SGLT-2). The gene discussed is SLC5A2; the disease is diabetes mellitus.